Vitiligo treatment holds promise for restoring skin pigmentation

September 17, 2014

DETROIT - A treatment regimen is safe and effective for restoring skin pigmentation in vitiligo patients, according to a Henry Ford Hospital study.

"Our findings offer patients with vitiligo worldwide a renewed hope for a bright future in the treatment of this disfiguring disease," says Henry Lim, M.D., chair of Dermatology at Henry Ford and the study's lead author. "Patients with lesions on their face and arms could have a more rapid response to the combination treatment."

Henry Ford dermatologists described the repigmentation results as "superior," and said the treatment combination holds promise as a future therapy for the more than 50 million people worldwide living with vitiligo. It affects about one in every 100 people in the United States.

The study will be published online Wednesday in the Journal of the American Medical Association-Dermatology.

In a multi-center study led by Henry Ford, dermatologists sought to evaluate the safety and effectiveness of a treatment combination of afamelanotide, a drug that induces skin pigmentation, and phototherapy using narrowband ultraviolet-B rays (NB UVB). Phototherapy, or ultraviolet light therapy, is the treatment of choice for many patients with widespread vitiligo. It has been shown to be effective, though the degree of repigmentation varies.

Dr. Lim, an international vitiligo expert, says afamelanotide "enhances the ability of the UVB to induce repigmentation of the skin."

Patients were randomly divided into two study groups: Group A received the combination therapy; Group B received only NB UVB treatment.

Key findings: Afamelanotide is in the process of being submitted for approval from the U.S. Food and Drug Administration for use in treating vitiligo.

Vitiligo is a skin disease that causes the skin to lose color and develop white patches that vary in size and location. It develops when cells called melanocytes are killed by the body's immune system, causing the area of skin to turn white because the cells no longer make pigment. Vitiligo is more noticeable in individuals with darker skin tones, but it affects all races and ethnicities.

While vitiligo is neither contagious nor life-threatening, there is no cure. However, it causes low self-esteem and depression for those living with the disease.

The Henry Ford study represents its latest research into investigating new treatment options for vitiligo. In a 2012 study published in the Journal of the American Academy of Dermatology, Henry Ford dermatologists showed the benefits of skin cell transplant surgery, called melanocyte-keratinocyte transplantation or MKTP. Henry Ford has since performed more than 190 MKTP procedures on patients from Michigan, 23 other U.S. states and Canada.

For this new study, 55 patients were enrolled at four sites - Henry Ford, Icahn School of Medicine at Mount Sinai in New York and Vitiligo and Pigmentation Institute of Southern California and University of California Davis' Department of Dermatology.

In the two study groups, 28 patients were enrolled in Group A and 27 patients in Group B. Both groups received phototherapy two to three times a week for six months for a total of 72 treatments. In addition to phototherapy, patients in Group A received a dose of 16 mg of afamelanotide in four monthly treatments. Afamelanotide, about the size of a grain of rice, was implanted just under the skin.

Two common vitiligo assessment scoring systems - Vitiligo Area Scoring Index and Vitiligo European Task Force - were used to evaluate the repigmentation response.

While patients in both groups showed repigmentation, the response in Group A was superior to Group B by the 56th day of treatment and even better by the 168th day of treatment. The most common side effect was redness of the skin.
-end-
The study was funded by Clinuvel Pharmaceuticals.

Henry Ford Health System

Related Vitiligo Articles from Brightsurf:

Immunotherapy side effect could be a positive sign for kidney cancer patients
An autoimmune side effect of immune checkpoint inhibitor (ICI) drugs could signal improved control of kidney cancer, according to a new study by researchers in UT Southwestern's Kidney Cancer Program (KCP).

Henry Ford study demonstrates UV-C light is effective for killing COVID-19 on N95s
Dermatology researchers at Henry Ford Health System, in collaboration with a team at the University of Michigan, have demonstrated that certain N95 respirators tainted with COVID-19 can be effectively and safely decontaminated for reuse using ultraviolet-C light (UV-C), a method commonly utilized for treating rare skin diseases.

Blocking nerve signals to the pancreas halts type 1 diabetes onset in mice
In a new Science Advances study, researchers at La Jolla Institute for Immunology (LJI) report that the nervous system may be driving this patchy cell die-off.

Nanosize device 'uncloaks' cancer cells in mice and reveals them to the immune system
Scientists at Johns Hopkins report they have designed and successfully tested an experimental, super small package able to deliver molecular signals that tag implanted human cancer cells in mice and make them visible for destruction by the animals' immune systems.

Shedding light on the reaction mechanism of PUVA light therapy for skin diseases
Together with their Munich-based colleagues, a team of physical chemists from Heinrich Heine University Düsseldorf (HHU) has clarified which chemical reactions take place during PUVA therapy.

New studies by CU researchers highlight causes of vitiligo
A pair of new journal articles by researchers at the University of Colorado School of Medicine indicate that both genetic and environmental factors play significant roles in the onset of vitiligo, an autoimmune disease that results in the loss of color in blotches of skin.

Topical cream shows promise in treatment of skin pigmentation disease, vitiligo
A nationwide phase II clinical trial, coordinated out of Tufts Medical Center in Boston, has found that a topical cream was extremely effective in reversing the effects of vitiligo, a relatively common autoimmune disease that causes loss of skin pigmentation.

People with benign skin condition willing to trade time, money to cure disorder
People with benign hyperpigmentation (the darkening or increase in the natural color of the skin), are willing to pay (WTP) nearly 14 percent of their monthly income and approximately 90 minutes a day to cure their condition.

Autoimmune diseases are related to each other, some more than others
Researchers using the world's largest twin registry to study seven autoimmune diseases found the risk of developing the seven diseases is largely inherited, but that some diseases are more closely related than others.

Yale experts treat severe, disfiguring sarcoidosis with novel therapy
An all-Yale team of researchers successfully treated a patient with disfiguring sarcoidosis, a chronic disease that can affect multiple organs, with a drug approved for rheumatoid arthritis.

Read More: Vitiligo News and Vitiligo Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.